To evaluate the efficacy of traditional Ayurvedic formulation (Divya Melanogrit) in Leukoderma.

Efficacy of traditional Ayurvedic formulation (Divya Melanogrit) in Leukoderma: a single arm, open label, observational study.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/02/049953

Enrollment

Registered

2023-02-22

Start date

Unknown

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who are known cases of leukoderma (vitiligo). 2. Age should be minimum of 18 years. 3. Patient who is willing to participate voluntary and comply throughout the study process. 4. Informed consent must be obtained

Exclusion criteria

Exclusion criteria: CRITERIA FOR INCLUSION AND EXCLUSION Inclusion criteria 1. Patients who are known cases of leukoderma (vitiligo). 2. Age should be minimum of 18 years. 3. Patient who is willing to participate voluntary and comply throughout the study process. 4. Informed consent must be obtained. Exclusion criteria 1. Patients who do not fulfill inclusion criteria must be excluded. 2. Known cases of Psoriasis, eczema or any other skin allergies patients will be excluded. 3. Patients who are currently undergoing any restricted therapy like UV phototherapy, Tar therapy, topical photo chemotherapy, oral and topical corticosteroids, immunomodulators, etc. will be excluded. 4. Patients who are pregnant, lactating and those who plan to become pregnant within a year. 5. Those with a history of primary cardiovascular, respiratory, digestive, urinary, endocrinological and haematological diseases that cannot be controlled with ordinary treatments will be excluded. 6. Those with malignant diseases, infections, electrolyte imbalances and acid-base disturbances will be excluded. 7. Patients who are allergic to any medicine or ingredients used in this study will be excluded. 8. Patients who are consuming steroids during the study duration must be excluded.

Design outcomes

Primary

Measure	Time frame
To evaluate the effectiveness and tolerability of Divya Melanogrit in patients with Leukoderma.Timepoint: Baseline, 12 weeks, 24 weeks	—

Secondary

Measure	Time frame
â?¢ Changes in the Vitiligo Extent Score (VES), Investigators Global Assessment (IGA), VIS-22, VitiQol and Global perceived treatment satisfaction from medication. Timepoint: DAY 0, DAY 90,DAY 180	—

Countries

India

Contacts

Public ContactDr Anurag Sharma

Patanjali Yog Gram

clinical.investigator@patanjali.res.in7302254792

Outcome results